title: Prime-O-glucosylcimifugin attenuates lipopolysaccharide-induced acute lung injury in mice.
abstract: Prime-O-glucosylcimifugin is an active chromone isolated from Saposhnikovia root which has been reported to have various activities, such as anti-convulsant, anticancer, anti-inflammatory properties. The purpose of this study was to evaluate the effect of prime-O-glucosylcimifugin on acute lung injury (ALI) induced by lipopolysaccharide in mice. BALB/c mice received intraperitoneal injection of Prime-O-glucosylcimifugin 1h before intranasal instillation (i.n.) of lipopolysaccharide (LPS). Concentrations of tumor necrosis factor (TNF)-α, interleukin (IL)-1β and interleukin (IL)-6 in bronchoalveolar lavage fluid (BALF) were measured by enzyme-linked immunosorbent assay (ELISA). Pulmonary histological changes were evaluated by hematoxylin-eosin, myeloperoxidase (MPO) activity in the lung tissue and lung wet/dry weight ratios were observed. Furthermore, the mitogen-activated protein kinases (MAPK) signaling pathway activation and the phosphorylation of IκBα protein were determined by Western blot analysis. Prime-O-glucosylcimifugin showed promising anti-inflammatory effect by inhibiting the activation of MAPK and NF-κB signaling pathway.
authors.affiliation: College of Animal Science and Veterinary Medicine, Jilin University, Changchun 130062, PR China.
authors.forename: Na
authors.initials: N
authors.lastname: Chen
authors.forename: Qianchao
authors.initials: Q
authors.lastname: Wu
authors.forename: Gefu
authors.initials: G
authors.lastname: Chi
authors.forename: Lanan Wassy
authors.initials: LW
authors.lastname: Soromou
authors.forename: Jinli
authors.initials: J
authors.lastname: Hou
authors.forename: Yanhong
authors.initials: Y
authors.lastname: Deng
authors.forename: Haihua
authors.initials: H
authors.lastname: Feng
mesh_terms: D055371:Acute Lung Injury / Q000188:drug therapy* / Q000209:etiology / Q000276:immunology / Q000473:pathology; D000818:Animals; D000893:Anti-Inflammatory Agents / Q000494:pharmacology / Q000627:therapeutic use*; D001992:Bronchoalveolar Lavage Fluid / Q000276:immunology; D002460:Cell Line; D016207:Cytokines / Q000276:immunology; D008070:Lipopolysaccharides; D008168:Lung / Q000276:immunology / Q000473:pathology; D008297:Male; D051379:Mice; D008807:Mice, Inbred BALB C; D020928:Mitogen-Activated Protein Kinases / Q000276:immunology; D009005:Monosaccharides / Q000494:pharmacology / Q000627:therapeutic use*; D016328:NF-kappa B / Q000276:immunology; D014966:Xanthenes / Q000494:pharmacology / Q000627:therapeutic use*
chemical_list: D000893:Anti-Inflammatory Agents; D016207:Cytokines; D008070:Lipopolysaccharides; D009005:Monosaccharides; D016328:NF-kappa B; D014966:Xanthenes; C498945:prim-O-glucosylcimifugin; D020928:Mitogen-Activated Protein Kinases